GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Enterprise Value
中文

Nymox Pharmaceutical (Nymox Pharmaceutical) Enterprise Value

: $27.92 Mil (As of Today)
View and export this data going back to 1997. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nymox Pharmaceutical's Enterprise Value is $27.92 Mil. Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.70 Mil. Therefore, Nymox Pharmaceutical's EV-to-EBIT ratio for today is -16.43.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Nymox Pharmaceutical's Enterprise Value is $27.92 Mil. Nymox Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.48 Mil. Therefore, Nymox Pharmaceutical's EV-to-EBITDA ratio for today is -18.86.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Nymox Pharmaceutical's Enterprise Value is $27.92 Mil. Nymox Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01 Mil. Therefore, Nymox Pharmaceutical's EV-to-Revenue ratio for today is -5,583.00.


Nymox Pharmaceutical Enterprise Value Historical Data

The historical data trend for Nymox Pharmaceutical's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.78 151.59 190.16 110.77 28.03

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.37 28.03 30.54 18.01 48.90

Competitive Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Enterprise Value falls into.



Nymox Pharmaceutical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Nymox Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Nymox Pharmaceutical's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Nymox Pharmaceutical's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=27.915/-1.699
=-16.43

Nymox Pharmaceutical's current Enterprise Value is $27.92 Mil.
Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Nymox Pharmaceutical's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=27.915/-1.48
=-18.86

Nymox Pharmaceutical's current Enterprise Value is $27.92 Mil.
Nymox Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.48 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Nymox Pharmaceutical's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=27.915/-0.005
=-5,583.00

Nymox Pharmaceutical's current Enterprise Value is $27.92 Mil.
Nymox Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023